Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

IRB/UVA Tracking #
17720
Contact
Gracie Hockenberry
Contact Email
Contact Phone
1.434.297.7784
Phase
III
Primary purpose
Treatment
Cancer PI
Richard Hall
Status
OPEN TO ACCRUAL
Ages
Adult